Prospective study of predictive markers in nivolumab immunotherapy

Prospective study of predictive markers in nivolumab immunotherapy - Prospective study of predictive markers in nivolumab immunotherapy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000024051

Enrollment

100

Registered

2016-09-14

Start date

2016-09-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: lung cancer patients over 20 years old treated with Nivolumab agreed to this study by a document

Exclusion criteria

Exclusion criteria: ruled unfit to this study by attending physician

Design outcomes

Primary

Measure	Time frame
Relationship between efficacy of nivolumab and immune complexes	—

Countries

Japan

Contacts

Public ContactTakaya Ikeda

Nagasaki University Hospital Second Department of Internal Medicine

ikedat@nagasaki-u.ac.jp095-819-7273

Outcome results